A new "weapon" against a super antibody and a cheap tablet HIV

American scientists have created a new super antibody that attacks 99% of HIV's HIV strains. The new antibody, which has been successfully tested in monkeys and can prevent its infection with the virus, attacks at three critical parts of the virus at the same time, which makes it more difficult for the protection of HIV.

Researchers from US National Institute of Health, Harvard and MIT Universities and Sanofi Pharmaceutical Company have made a relevant publication in journal science. According to the BBC, tests on humans will start in 2018.

Difficulty fighting HIV is due to the fact that the virus has an effective ability to mutate, resulting in a large number of HIV stresses. After several years of infection, some patients can develop naturally strong antibodies, which can kill many different strains of the virus.

Scientists have long been trying to use these natural antibodies to treat these patients or to prevent infection. Now, for the first time, three such natural antibodies have been added to a new powerful triple antibody, which is more effective than any natural anti-HIV antibody.

The most powerful natural antibodies can attack up to 90% of the stress of the virus, while the new super antibody reaches 99% and even lower levels in the body. Experiments from 24 animals treated with triple antibodies have shown that none of these was for HIV when it was later infected with it.

The scientific officer of Sanofi, Dr. Gary Neibel, spoke for "the impressive level of security". Professor Linda-Gayle Baker, president of the International AIDS Society spoke of "exciting progress"

A pellet shot for AIDS

At a cost of less than $ 75 per year, the government of South Africa and Kenya can soon treat an AIDS patient with a combination of three antiretroviral drugs (ARV) combination.

The main drug of the new tablet will be Dolittlegraveer, a powerful and safe ARV drug, which has so far become very expensive for countries with lowest and middle income. The annual cost per year for the new yellow, which is related to the general category, will be approximately $ 25 from current cheapest triple combination of available ARV drugs on the market.

According to Science, the announcement was made by Michel Syndib, Head of the United Nations Program on HIV / AIDS, according to United Nations AIDS in a press conference in Geneva. As mentioned, it is hoped that the new pill will help AIDS in the efforts of around 37 million people worldwide, out of which only 19.5 million people are treating with ARV.

The new pill will be a 'first line' treatment with a new 'profile': the ability to fight high HIV, low toxicity and ease of use, which will help patients to make it easier for a lifetime, thereby reducing the chances of recurrence The other two drugs of triple cocktail of the virus are lamivudine and tanofovir, which are already widely used.

South Africa, the country in which HIV is infected and the biggest buyer of ARV drugs, is hopeful that thanks to the new treble pill will save $ 900 million in a six-year period. UNAIDS said that the goal is to finally create a tablet available for 92 countries.